SEATTLE, WA--(Marketwired - Jul 22, 2015) - Atossa Genetics Inc. (NASDAQ: ATOS) today announced that its subsidiary, The National Reference Laboratory for Breast Health Inc. (the NRLBH), now provides a new expanded pharmacogenetic test based on technology and equipment provided by Luminex Corporation (NASDAQ: LMNX). The NRLBH is the first commercial laboratory to develop and now offer the new pharmacogenetic test with expanded genetic targets utilizing Luminex's xTAG® technology platform. 

"We are very excited to be the first commercial laboratory in the U.S. to offer our enhanced pharmacogenetic test based on Luminex xTAG technology as it provides doctors and patients with even greater insights into treatment protocols," said Dr. Steven Quay, Chairman, CEO & President of Atossa Genetics.

The new expanded pharmacogenetic test includes a genetic analysis of 8 additional genes. The genetic information provided by the new test helps physicians treat certain addictions and a variety of clinical conditions including depression, anxiety, and other behavioral health issues.

"The new pharmacogenetics test from Atossa Genetics demonstrates the growing clinical utility of Luminex technology in the fast-growing field of pharmacogenetics (or personalized medicine)," said Homi Shamir, President and CEO of Luminex. "We are excited to partner with Atossa in their goal of transforming healthcare and improving patient outcomes."

About Atossa Genetics

Atossa Genetics Inc. is focused on improving breast health through the development of laboratory services, medical devices and therapeutics. The laboratory services are being developed by its subsidiary, The National Reference Laboratory for Breast Health Inc. The laboratory services and the Company's medical devices are being developed so they can be used as companions to therapeutics to treat various breast health conditions. For more information, please visit

About Luminex Corporation

Luminex is committed to applying its passion for innovation toward creating breakthrough solutions to improve health and advance science. The company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP® open-architecture multi-analyte platform, MultiCode® real-time polymerase chain reaction (PCR), and multiplex PCR-based technologies, that deliver cost-effective rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories, as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. Luminex is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, biodefense research, and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology, please visit

For more information on Luminex's pharmacogenetic assays, visit: or

Learn more about the Personalized Medicine Coalition: The expanded pharmacogenetic test is a laboratory developed test (LDT) and is not FDA-cleared or approved.

Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, the outcome or timing of regulatory approvals needed by Atossa to sell its products, responses to regulatory matters, Atossa's ability to achieve its objectives, continue to manufacture and sell its products, recalls of products, the safety and efficacy of Atossa's products and services, performance of distributors, whether Atossa can launch and commercialize in the United States and foreign markets the additional tests, devices and therapeutics in its pipeline in a timely and cost effective manner, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time. Atossa does not undertake any obligation to update any forward-looking statement.

Contact Information:


Atossa Genetics, Inc.
Kyle Guse
CFO and General Counsel
(O) 800-351-3902

Investor Relations:
CorProminence LLC
Scott Gordon

Luminex Investor Contact
Harriss Currie
Sr. Vice President of Finance and CFO

Luminex Media Contact
Christine Valle
Sr. Manager, Global Marketing